EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)

Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1)

Vassilios Aslanis iD, Khalid Abd-Elaziz iD, Robert J Slack iD, Anne Brinch, Lise Gravelle, Wayne Morley, De Phung, Kimberly Herman iD, Ian Holyer, Karen Killerup Poulsen, Peter Dogterom, Susan Tantawi iD und 4 weitere

Cancer Chemotherapy and Pharmacology · 2024

DOI: 10.1007/s00280-024-04710-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Vassilios Aslanis und 15 weiteren Autor:innen. Beteiligte Einrichtung: Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark. v.aslanis@gmail.com. Hauptthemen laut MEDLINE: Cross-Over Studies, Biological Availability, Tablets, Food-Drug Interactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Galecto Biotech AB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cross-Over StudiesBiological AvailabilityTabletsFood-Drug InteractionsHealthy VolunteersHumansMaleAdultFemaleYoung AdultMiddle AgedAdministration, OralCapsulesFastingGalectin 3Area Under CurveBlood ProteinsGalectins

Stichwörter der Autor:innen

BioavailabilityFood effectGalectin-3SelvigaltinTablet formulation

Substanzen

TabletsCapsulesLGALS3 protein, humanGalectin 3Blood ProteinsGalectins

Autor:innen und Institutionen

  • Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark. v.aslanis@gmail.com.
  • QPS Netherlands BV, Groningen, The Netherlands.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.
  • Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark.

ORCID-Profile: Vassilios Aslanis, Khalid Abd-Elaziz, Robert J Slack, Kimberly Herman, Susan Tantawi, Fredrik R Zetterberg

Förderung

  • Galecto Biotech AB

Zitieren

APA

Aslanis, V., Abd-Elaziz, K., Slack, R. J., Brinch, A., Gravelle, L., Morley, W., Phung, Herman, K., Holyer, I., Poulsen, K. K., Dogterom, P., Tantawi, S., Zetterberg, F. R., Jacoby, B., Schambye, H., & Lindmark, B. (2024). Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1). Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04710-3

Vancouver

Aslanis V, Abd-Elaziz K, Slack RJ, Brinch A, Gravelle L, Morley W, et al. Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1). Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04710-3

BibTeX
@article{Aslanis2024,
  author = {Aslanis, Vassilios and Abd-Elaziz, Khalid and Slack, Robert J and Brinch, Anne and Gravelle, Lise and Morley, Wayne and Phung, De and Herman, Kimberly and Holyer, Ian and Poulsen, Karen Killerup and Dogterom, Peter and Tantawi, Susan and Zetterberg, Fredrik R and Jacoby, Brian and Schambye, Hans and Lindmark, Bertil},
  title = {Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1)},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  doi = {10.1007/s00280-024-04710-3}
}
Kostenlos starten →